Study: NCT03155893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV Placebo (Matching 25 mg ODV)
Description: Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV Placebo (Matching 25 mg ODV)
Description: Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV Placebo (Matching 25 mg ODV)
Description: Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ODV Placebo (Matching 200 mg ODV)
Description: Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ODV Placebo (Matching 125 mg ODV)
Description: Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ODV Placebo (Matching 100 mg ODV)
Description: Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV Placebo (Matching 150 mg SMV)
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV Placebo (Matching 150 mg SMV)
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV Placebo (Matching 150 mg SMV)
Description: Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 Placebo (matching 1200 mg AL-335)
Description: Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 Placebo (matching 1200 mg AL-335)
Description: Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Description: Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Description: Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo (matching 400 mg moxifloxacin)
Description: Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 25 mg
Description: Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 200 mg
Description: Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 125 mg
Description: Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODV 100 mg
Description: Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.